Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial - Litton, J K; Hurvitz, S A; Mina, L A (Ann Oncol, 2020)